Results 171 to 180 of about 84,152 (313)

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

The big bang as a result of the first-order phase transition driven by a change of the scalar curvature in an expanding early Universe: The “hyperinflation” scenario [PDF]

, 2016
É. A. Pashitskiı̆, В. И. Пентегов   +1 more
openalex   +1 more source

Multi‐Omics Integration for Advancing Glioma Precision Medicine

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Gliomas are among the most malignant and aggressive tumors of the central nervous system, characterized by the absence of early diagnostic markers, poor prognosis, and a lack of effective treatments. Advances in high‐throughput technologies have facilitated a refined molecular classification of gliomas, incorporating genetic features. However,
Maria Guarnaccia, Valentina La Cognata, Giulia Gentile, Giovanna Morello, Sebastiano Cavallaro   +4 more
wiley   +1 more source

Magnetic Confinement of a Bubble of Supercooled ³He-A. [PDF]

J Low Temp Phys
Whitehead L, Casey A, Haley RP, Heikkinen PJ, Levitin LV, Mayer AJ, Rojas X, Salmon T, Saunders J, Thomson A, Zmeev DE, Autti S.   +11 more
europepmc   +1 more source

Phase Transition in Early Universe with Two Higgs Doublets

, 2023
Anh Tuan Nguyen, Thanh Tam Dinh
openalex   +1 more source

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer, Frauke Stascheit, Maximilian Mönch, Paolo Doksani, Carla Dusemund, Meret Herdick, Philipp Mergenthaler, Maike Stein, Amani Suboh, Jutta Schröder‐Braunstein, Guido Wabnitz, Jan D. Lünemann, Sophie Lehnerer, Sarah Hoffmann, Andreas Meisel   +14 more
wiley   +1 more source

Origins of life: the possible and the actual. [PDF]

Philos Trans R Soc Lond B Biol Sci
Solé R, Kempes C, Stepney S.
europepmc   +1 more source

Where, How, and How Much? A Multicenter Cohort Study of the Relationship Across Lupus Decision‐Aid Modality, Place of Administration, Interruption and Viewing Completeness, and Patient‐Reported Outcomes

Arthritis Care &Research, EarlyView.
Objective We assessed whether shared decision‐making (SDM) and patient acceptability, feasibility, and overall satisfaction with a computerized patient decision aid (PtDA) for patients with systemic lupus erythematosus (SLE) differs by PtDA setting, modality, and the viewing experience. Methods Patients with SLE were invited to view a self‐administered
Jasvinder A. Singh, Mark Beasley, Larry R. Hearld, for the Implementing Decision‐Aid for Lupus in Clinics (IDEAL) Consortium, Winn Chatham, Jasvinder Singh, Sonali Narain, Narender Annapureddy, Diane Kamen, Kimberly Trotter, Vikas Majithia, Cathy Ching, Zineb Aouhab, Swamy Venturupalli, Rosalind Ramsey‐Goldman, Alfred Kim, Maureen McMahon, Sam Lim, Kalpana Bhairavarasu, Alexa Meara, Kenneth Kalunian   +20 more
wiley   +1 more source

Is the emergence of life and of agency expected? [PDF]

Philos Trans R Soc Lond B Biol Sci
Kauffman S, Roli A.
europepmc   +1 more source

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source